Abstract Library

#2844 Rectal Neuroendocrine Tumor with Chromogranin Expression Is Associated with Aggressive Clinical Behavior and Worse Prognosis

Introduction: Although rectal neuroendocrine tumors (NETs) with L-cell phenotype and small tumor size generally had better clinical behavior, the new 2019 WHO classification classified all rectal NETs are malignant without considering L-cell phenotype and small tumor size. Therefore, identifying biomarkers of rectal NETs is important to stratify the clinical behavior of rectal NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kim J

Authors: Kim J, Kim J, Oh E, Yang D, Hong S,

Keywords: Rectal neuroendocrine tumor, Chromogranin, Immunohistochemistry, Prognosis,

#1783 Gastroenteropancreatic High-Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 6291 Cases

Introduction: Knowledge about gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) is scarce given their low incidence rates and aggressive clinical behavior

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Dasari A, Mehta K, Sorbye H, Yao J,

Keywords: Grade 3, NE carcinoma,

#1477 Neuroendocrine Tumors of the Biliary Tract: A Retrospective, Observational Multicenter Study

Introduction: Neuroendocrine tumors of the biliary tract (BTNETs) constitute a heterogeneous group of neoplasms. Because of their rarity, the clinical behavior is unclear.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Brizzi M, Massironi S, Pusceddu S, De Nigris B, Birocco N,

Keywords: Biliary tract NET,

#1192 Clinical Characteristics and Overall Survival of Large Cell Neuroendocrine Carcinoma (LCNEC) Compared to Other Subtypes of Lung Cancer: Results of a Population-based Registry

Introduction: LCNEC is a rare non-small cell lung cancer subtype and clinical behavior is unclear.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Derks J

Authors: Derks J, Hendriks L, Damhuis R, Speel E, Dingemans A,

Keywords: LCNEC, lung,

#1172 Dual Inhibition of PI3K and mTORC1/C2 by PKI-587 (PF-05212384) as a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease and Its Effect on AKT-Signaling

Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are heterogeneous in their clinical behavior and therapeutic options are still not satisfactory. The “crosstalk” of different signaling pathways in NEN cells appears to be more complex as known already. PKI-587 is a highly potent novel dual inhibitor of PI3K and mTORC1/C2.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Freitag H, Briest F, Christen F, Grass I, Lewens F,

Keywords: dual inhibition, PI3K, mTOR, PKI-587,RAD001, signaling,